Yanlaoda personal page - To The Moon

Yanlaoda

Yanlaoda

No personal profile

17Follow

0Followers

0Topic

0Badge

2021-07-16

$SGOCO Group Ltd(SGOC)$fly pls

2021-07-16

Ded

Bit Brother shares tumbles 44% on pricing $22.5M registered direct offering

2021-06-28

Hmm going where next

2021-06-25

Hahaha

Sorry, the original content has been removed

2021-06-25

?

Sorry, the original content has been removed

2021-05-06

Hi

Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver

2021-05-06

Got it using voucher

2021-05-06

Should buy?

Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver

2021-05-06

Should i buy?

2021-04-14

Interesting

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3581383545797757,"uuid":"3581383545797757","gmtCreate":1618290680025,"gmtModify":1618401007498,"name":"Yanlaoda","pinyin":"yanlaoda","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":17,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":170416757,"gmtCreate":1626445517179,"gmtModify":1703760382883,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SGOC\">$SGOCO Group Ltd(SGOC)$</a>fly pls","listText":"<a href=\"https://laohu8.com/S/SGOC\">$SGOCO Group Ltd(SGOC)$</a>fly pls","text":"$SGOCO Group Ltd(SGOC)$fly pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170416757","isVote":1,"tweetType":1,"viewCount":178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170411705,"gmtCreate":1626445469807,"gmtModify":1703760379591,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ded","listText":"Ded","text":"Ded","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170411705","repostId":"1146338800","repostType":4,"repost":{"id":"1146338800","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626444143,"share":"https://www.laohu8.com/m/news/1146338800?lang=&edition=full","pubTime":"2021-07-16 22:02","market":"us","language":"en","title":"Bit Brother shares tumbles 44% on pricing $22.5M registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=1146338800","media":"Tiger Newspress","summary":"Bit Brother Limited down 44% in earlytrading on selling 15M ordinary shares and warrants to purchase","content":"<p>Bit Brother Limited&nbsp;down&nbsp;44%&nbsp;in&nbsp;earlytrading on&nbsp;selling&nbsp;15M ordinary shares and warrants to purchase 15M ordinary shares&nbsp;in a registered direct&nbsp;offering for gross proceeds of $22.5M.</p>\n<p><img src=\"https://static.tigerbbs.com/88386920b490db76cf64dd8aa93a11d8\" tg-width=\"1296\" tg-height=\"610\" referrerpolicy=\"no-referrer\"></p>\n<p>The purchase price for one ordinary share and one corresponding five-years warrant will be $1.50.</p>\n<p>Offering is expected to close on July 20.</p>\n<p>Earlier this week,the company acquired 51% stake in Angelo's Pizza for $12.5M.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bit Brother shares tumbles 44% on pricing $22.5M registered direct offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBit Brother shares tumbles 44% on pricing $22.5M registered direct offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-16 22:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Bit Brother Limited&nbsp;down&nbsp;44%&nbsp;in&nbsp;earlytrading on&nbsp;selling&nbsp;15M ordinary shares and warrants to purchase 15M ordinary shares&nbsp;in a registered direct&nbsp;offering for gross proceeds of $22.5M.</p>\n<p><img src=\"https://static.tigerbbs.com/88386920b490db76cf64dd8aa93a11d8\" tg-width=\"1296\" tg-height=\"610\" referrerpolicy=\"no-referrer\"></p>\n<p>The purchase price for one ordinary share and one corresponding five-years warrant will be $1.50.</p>\n<p>Offering is expected to close on July 20.</p>\n<p>Earlier this week,the company acquired 51% stake in Angelo's Pizza for $12.5M.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146338800","content_text":"Bit Brother Limited down 44% in earlytrading on selling 15M ordinary shares and warrants to purchase 15M ordinary shares in a registered direct offering for gross proceeds of $22.5M.\n\nThe purchase price for one ordinary share and one corresponding five-years warrant will be $1.50.\nOffering is expected to close on July 20.\nEarlier this week,the company acquired 51% stake in Angelo's Pizza for $12.5M.","news_type":1},"isVote":1,"tweetType":1,"viewCount":186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127605190,"gmtCreate":1624845022110,"gmtModify":1703845994642,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hmm going where next","listText":"Hmm going where next","text":"Hmm going where next","images":[{"img":"https://static.tigerbbs.com/82bdc2ef24237999211614ebf981f04a","width":"1080","height":"2187"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127605190","isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":126425073,"gmtCreate":1624582357692,"gmtModify":1703840845168,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hahaha","listText":"Hahaha","text":"Hahaha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126425073","repostId":"1133896473","repostType":4,"isVote":1,"tweetType":1,"viewCount":187,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126426882,"gmtCreate":1624582313146,"gmtModify":1703840842745,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126426882","repostId":"1160571601","repostType":4,"isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105544380,"gmtCreate":1620313132240,"gmtModify":1704341861870,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/105544380","repostId":"1139680950","repostType":4,"repost":{"id":"1139680950","pubTimestamp":1620311931,"share":"https://www.laohu8.com/m/news/1139680950?lang=&edition=full","pubTime":"2021-05-06 22:38","market":"us","language":"en","title":"Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver","url":"https://stock-news.laohu8.com/highlight/detail?id=1139680950","media":"reuters","summary":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for ","content":"<p>Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.</p><p>Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.</p><p>\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.</p><p>The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.</p><p>However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.</p><p>The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.</p><p>Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.</p><p>Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.</p><p>It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.</p><p>Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.</p><p>\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.</p><p>Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.</p><p>Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal pharma shares sink as Biden backs COVID-19 vaccine IP waiver\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 22:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/><strong>reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139680950","content_text":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.","news_type":1},"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105545553,"gmtCreate":1620313103072,"gmtModify":1704341861223,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Got it using voucher","listText":"Got it using voucher","text":"Got it using voucher","images":[{"img":"https://static.tigerbbs.com/1f3d116878ab1c069b6d8b57e553a6bd","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/105545553","isVote":1,"tweetType":1,"viewCount":146,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":105542720,"gmtCreate":1620313043160,"gmtModify":1704341860253,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Should buy?","listText":"Should buy?","text":"Should buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/105542720","repostId":"1139680950","repostType":4,"repost":{"id":"1139680950","pubTimestamp":1620311931,"share":"https://www.laohu8.com/m/news/1139680950?lang=&edition=full","pubTime":"2021-05-06 22:38","market":"us","language":"en","title":"Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver","url":"https://stock-news.laohu8.com/highlight/detail?id=1139680950","media":"reuters","summary":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for ","content":"<p>Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.</p><p>Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.</p><p>\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.</p><p>The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.</p><p>However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.</p><p>The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.</p><p>Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.</p><p>Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.</p><p>It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.</p><p>Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.</p><p>\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.</p><p>Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.</p><p>Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal pharma shares sink as Biden backs COVID-19 vaccine IP waiver\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 22:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/><strong>reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139680950","content_text":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.","news_type":1},"isVote":1,"tweetType":1,"viewCount":215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105546865,"gmtCreate":1620312965257,"gmtModify":1704341858801,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Should i buy?&nbsp;","listText":"Should i buy?&nbsp;","text":"Should i buy?","images":[{"img":"https://static.tigerbbs.com/b881e80f965bbcb835d67d3fba6e8cea","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/105546865","isVote":1,"tweetType":1,"viewCount":90,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":344841507,"gmtCreate":1618400895309,"gmtModify":1704710215520,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[{"img":"https://static.tigerbbs.com/51a668513b58e6a6154d6de16c9d21c7","width":"1080","height":"2007"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344841507","isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":126425073,"gmtCreate":1624582357692,"gmtModify":1703840845168,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hahaha","listText":"Hahaha","text":"Hahaha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126425073","repostId":"1133896473","repostType":4,"isVote":1,"tweetType":1,"viewCount":187,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105542720,"gmtCreate":1620313043160,"gmtModify":1704341860253,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Should buy?","listText":"Should buy?","text":"Should buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/105542720","repostId":"1139680950","repostType":4,"repost":{"id":"1139680950","pubTimestamp":1620311931,"share":"https://www.laohu8.com/m/news/1139680950?lang=&edition=full","pubTime":"2021-05-06 22:38","market":"us","language":"en","title":"Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver","url":"https://stock-news.laohu8.com/highlight/detail?id=1139680950","media":"reuters","summary":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for ","content":"<p>Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.</p><p>Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.</p><p>\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.</p><p>The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.</p><p>However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.</p><p>The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.</p><p>Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.</p><p>Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.</p><p>It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.</p><p>Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.</p><p>\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.</p><p>Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.</p><p>Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal pharma shares sink as Biden backs COVID-19 vaccine IP waiver\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 22:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/><strong>reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139680950","content_text":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.","news_type":1},"isVote":1,"tweetType":1,"viewCount":215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170411705,"gmtCreate":1626445469807,"gmtModify":1703760379591,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ded","listText":"Ded","text":"Ded","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170411705","repostId":"1146338800","repostType":4,"repost":{"id":"1146338800","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626444143,"share":"https://www.laohu8.com/m/news/1146338800?lang=&edition=full","pubTime":"2021-07-16 22:02","market":"us","language":"en","title":"Bit Brother shares tumbles 44% on pricing $22.5M registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=1146338800","media":"Tiger Newspress","summary":"Bit Brother Limited down 44% in earlytrading on selling 15M ordinary shares and warrants to purchase","content":"<p>Bit Brother Limited&nbsp;down&nbsp;44%&nbsp;in&nbsp;earlytrading on&nbsp;selling&nbsp;15M ordinary shares and warrants to purchase 15M ordinary shares&nbsp;in a registered direct&nbsp;offering for gross proceeds of $22.5M.</p>\n<p><img src=\"https://static.tigerbbs.com/88386920b490db76cf64dd8aa93a11d8\" tg-width=\"1296\" tg-height=\"610\" referrerpolicy=\"no-referrer\"></p>\n<p>The purchase price for one ordinary share and one corresponding five-years warrant will be $1.50.</p>\n<p>Offering is expected to close on July 20.</p>\n<p>Earlier this week,the company acquired 51% stake in Angelo's Pizza for $12.5M.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bit Brother shares tumbles 44% on pricing $22.5M registered direct offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBit Brother shares tumbles 44% on pricing $22.5M registered direct offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-16 22:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Bit Brother Limited&nbsp;down&nbsp;44%&nbsp;in&nbsp;earlytrading on&nbsp;selling&nbsp;15M ordinary shares and warrants to purchase 15M ordinary shares&nbsp;in a registered direct&nbsp;offering for gross proceeds of $22.5M.</p>\n<p><img src=\"https://static.tigerbbs.com/88386920b490db76cf64dd8aa93a11d8\" tg-width=\"1296\" tg-height=\"610\" referrerpolicy=\"no-referrer\"></p>\n<p>The purchase price for one ordinary share and one corresponding five-years warrant will be $1.50.</p>\n<p>Offering is expected to close on July 20.</p>\n<p>Earlier this week,the company acquired 51% stake in Angelo's Pizza for $12.5M.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146338800","content_text":"Bit Brother Limited down 44% in earlytrading on selling 15M ordinary shares and warrants to purchase 15M ordinary shares in a registered direct offering for gross proceeds of $22.5M.\n\nThe purchase price for one ordinary share and one corresponding five-years warrant will be $1.50.\nOffering is expected to close on July 20.\nEarlier this week,the company acquired 51% stake in Angelo's Pizza for $12.5M.","news_type":1},"isVote":1,"tweetType":1,"viewCount":186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126426882,"gmtCreate":1624582313146,"gmtModify":1703840842745,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126426882","repostId":"1160571601","repostType":4,"repost":{"id":"1160571601","pubTimestamp":1624582048,"share":"https://www.laohu8.com/m/news/1160571601?lang=&edition=full","pubTime":"2021-06-25 08:47","market":"us","language":"en","title":"Cathie Wood’s ARK Innovation turns positive for the year as growth stocks surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1160571601","media":"CNBC","summary":"After a tumultuous first half of 2021, Cathie Wood’s flagship fund —ARK Innovation— just went positi","content":"<div>\n<p>After a tumultuous first half of 2021, Cathie Wood’s flagship fund —ARK Innovation— just went positive for the year as investors begin to give growth names a nod.\nThe actively managed ETF rose 1.5% on...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/24/cathie-woods-ark-innovation-turns-positive-for-the-year.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood’s ARK Innovation turns positive for the year as growth stocks surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood’s ARK Innovation turns positive for the year as growth stocks surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 08:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/24/cathie-woods-ark-innovation-turns-positive-for-the-year.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After a tumultuous first half of 2021, Cathie Wood’s flagship fund —ARK Innovation— just went positive for the year as investors begin to give growth names a nod.\nThe actively managed ETF rose 1.5% on...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/24/cathie-woods-ark-innovation-turns-positive-for-the-year.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","TDOC":"Teladoc Health Inc.","SHOP":"Shopify Inc"},"source_url":"https://www.cnbc.com/2021/06/24/cathie-woods-ark-innovation-turns-positive-for-the-year.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1160571601","content_text":"After a tumultuous first half of 2021, Cathie Wood’s flagship fund —ARK Innovation— just went positive for the year as investors begin to give growth names a nod.\nThe actively managed ETF rose 1.5% on Thursday, bringing its year-to-date gain to just shy of 1%. The innovation fund has rallied 5.4% this week and over 11% this month.\nSince bottoming on May 13 — a day after thehottest inflation reading since 2008— the fund is up about 25%.\n\nARK Innovation started to suffer in late February when a striking rotation from growth to value occurred in the market. However, fears of higher interest rates triggered by inflation appear overblown, as the U.S. 10-year Treasury sits around 1.5% after hitting a high near 1.8% at the end of March.\nWith interest rates continuing to come down and the threat of inflation under control, investors are now shifting back to their favorite growth names, and Wood’s Ark Invest is back on an upswing.\nWood called the comeback earlier this month. She told clients“the rotation back to growth is probably close at hand”on June 8.\nWood’s theory is that consumer spending is going to make a major move to the services sector after dominating in the goods sector during the coronavirus pandemic. Wood presciently said this would spur a decline in commodity prices and cyclical stocks, setting the stage for outperformance in innovation names.\nTo be sure, the fund has a long way to go to breach its record high from February. The ETF sits about 21% from its 52-week high.\nPower in ARK’s top holdings\nWood — known for taking advantage of dips in her highest conviction picks — spent the last few volatile months doubling down on her top holdings. Recently, Wood — a longtime bitcoin bull — has taken advantage of weakness inDraftKings,CoinbaseandGrayscale Bitcoin Trust.\n“We have capitalized on this volatility by selling names that have held up better than others and moving into names ... those that we have a high degree of conviction and those that are more opportunistic,” shesaid during an ARK webinarthis month. Wood told CNBC last month she now expects a 25% annual rate of return in her top holdings over the next five years.\nSince April’s hot inflation report released on May 12, Wood’s top holdings bottomed out and have led the ETF higher.\nCNBC Pro arranged the fund’s holding based on market valuation and screened for how much the equities have gained since then.\nShares of Tesla— the fund’s largest holding — are up roughly 15% since mid-May as of Wednesday’s close.\nAs of Wednesday’s close,Teladoc Health and Shopify are up about 20% and 43%, respectively, since the May bottom.Squarehas gained 21% andZoom Videohas popped 30% since then.TwilioandUnity Softwareare up 37% and 40% since the May bottom, respectively. DocuSign is up a whopping 52% in that time.\nWood made a name for herself after a banner 2020 where ARK Innovation returned nearly 150%.\nARK Innovation has seen roughly $7 billion of investor money enter the ETF in 2021, according to FactSet. In the past year, the $15 billion in fund flows have rushed Wood’s flagship fund.","news_type":1},"isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105544380,"gmtCreate":1620313132240,"gmtModify":1704341861870,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/105544380","repostId":"1139680950","repostType":4,"repost":{"id":"1139680950","pubTimestamp":1620311931,"share":"https://www.laohu8.com/m/news/1139680950?lang=&edition=full","pubTime":"2021-05-06 22:38","market":"us","language":"en","title":"Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver","url":"https://stock-news.laohu8.com/highlight/detail?id=1139680950","media":"reuters","summary":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for ","content":"<p>Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.</p><p>Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.</p><p>\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.</p><p>The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.</p><p>However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.</p><p>The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.</p><p>Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.</p><p>Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.</p><p>It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.</p><p>Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.</p><p>\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.</p><p>Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.</p><p>Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal pharma shares sink as Biden backs COVID-19 vaccine IP waiver\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 22:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/><strong>reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139680950","content_text":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.","news_type":1},"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170416757,"gmtCreate":1626445517179,"gmtModify":1703760382883,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SGOC\">$SGOCO Group Ltd(SGOC)$</a>fly pls","listText":"<a href=\"https://laohu8.com/S/SGOC\">$SGOCO Group Ltd(SGOC)$</a>fly pls","text":"$SGOCO Group Ltd(SGOC)$fly pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170416757","isVote":1,"tweetType":1,"viewCount":178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127605190,"gmtCreate":1624845022110,"gmtModify":1703845994642,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hmm going where next","listText":"Hmm going where next","text":"Hmm going where next","images":[{"img":"https://static.tigerbbs.com/82bdc2ef24237999211614ebf981f04a","width":"1080","height":"2187"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127605190","isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":105545553,"gmtCreate":1620313103072,"gmtModify":1704341861223,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Got it using voucher","listText":"Got it using voucher","text":"Got it using voucher","images":[{"img":"https://static.tigerbbs.com/1f3d116878ab1c069b6d8b57e553a6bd","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/105545553","isVote":1,"tweetType":1,"viewCount":146,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":105546865,"gmtCreate":1620312965257,"gmtModify":1704341858801,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Should i buy?&nbsp;","listText":"Should i buy?&nbsp;","text":"Should i buy?","images":[{"img":"https://static.tigerbbs.com/b881e80f965bbcb835d67d3fba6e8cea","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/105546865","isVote":1,"tweetType":1,"viewCount":90,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":344841507,"gmtCreate":1618400895309,"gmtModify":1704710215520,"author":{"id":"3581383545797757","authorId":"3581383545797757","name":"Yanlaoda","avatar":"https://static.tigerbbs.com/1e3e57d7496e60762eca18e1076432de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[{"img":"https://static.tigerbbs.com/51a668513b58e6a6154d6de16c9d21c7","width":"1080","height":"2007"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344841507","isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}